TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23750465
Drug: High treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High treatment dose (high attendance, exposure completion)
Study: 23750465
Drug: Low treatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low treatment dose (low attendance, exposure completion)
Study: 21445641
Drug: Intravenous selenite
Normalized name: selenite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous selenite as a bolus-loading dose of 2,000 μg Se followed by continuous infusion of 1,600 μg Se per day for 10 days
Study: 21445641
Drug: Intravenous selenite
Normalized name: selenite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous selenite
Study: 18279770
Drug: Irbesartan (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (not specified dosage or duration)
Study: 14586350
Drug: Combination misoprostol-Foley
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination misoprostol-Foley catheter
Study: 10722450
Drug: Intranasal zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intranasal zanamivir
Study: 11058672
Drug: Inhaled zanamivir
Normalized name: zanamivir Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled zanamivir
Study: 10722450
Drug: Inhaled plus
Normalized name: Duramist Plus Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled plus intranasal zanamivir
Study: 7788012
Drug: GHRH, Insulin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH, Insulin, Clonidine
Study: 517586
Drug: 2,000 U
Normalized name: AHF 2,000 UNIT/VWF 800 UNIT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 U heparin/12 hr subcutaneously
Study: 517586
Drug: 5,000 U
Normalized name: Decara 25,000 UNT Vegicaps
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 U heparin/12 hr subcutaneously
Study: 16507190
Drug: 0.015 mg
Normalized name: sulfur 0.015 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015 mg morphine (Group I, n=25)
Study: 16507190
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg morphine (Group II, n=30)
Study: 16507190
Drug: 0.06 mg
Normalized name: urea 0.06 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg morphine (Group III, n=31)
Study: 16507190
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg morphine (Group IV, n=33)
Study: 16507190
Drug: All morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: All morphine groups
Study: 2902264
Drug: Edmonston-Zagreb (EZ)
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb (EZ) measles vaccine, 40,000 PFU at 4 months of age
Study: 2902264
Drug: Schwarz measles
Normalized name: measles virus vaccine live, attenuated Schwarz strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz measles vaccine, 6000 TCID50 at 9 months of age
Study: 2902264
Drug: EZ vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZ vaccine
Study: 23447519
Drug: Cholic acid
Normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cholic acid (CA) 15 mg/kg per day
Study: 21374656
Drug: PEG‐IFN/ribavirin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN/ribavirin therapy
Study: 11103114
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg of urapidil (group U, n = 22)
Study: 11103114
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg of urapidil (group U)
Study: 9179227
Drug: Therapeutic doses
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic doses of 90Y-DOTA-peptide-ChL6
Study: 9179227
Drug: Tracer doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tracer doses of 111In-DOTA-peptide-ChL6
Study: 1489548
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of paroxetine, a serotonin re-uptake inhibitor
Study: 2857117
Drug: Nizatidine 6.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 6.25, 25, 75, 150, or 250 mg (single 20-min intravenous infusion)
Study: 2857117
Drug: Nizatidine 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 25, 50, 100, or 250 mg (5-min intravenous infusion weekly for 6 weeks)
Study: 2857117
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg (5-min intravenous infusion weekly for 6 weeks)
Study: 2857117
Drug: Placebo (5-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5-min intravenous infusion weekly for 6 weeks)
Study: 21977812
Drug: Zaizhang Shengxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaizhang Shengxue Tablet
Study: 11309012
Drug: B‐IINB (ilioinguinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: B‐IINB (ilioinguinal and iliohypogastric nerve block) with 10 ml of 0.5% bupivacaine
Study: 359083
Drug: Oral neomycin
Normalized name: neomycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neomycin and metronidazole added to bowel preparation
Study: 359083
Drug: Standard mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard mechanical preparation
Study: 28557585
Drug: IMRT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT and concurrent 5-FU/MMC
Study: 19586142
Drug: Therapeutic alliance
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic alliance intervention (TA) added to usual treatment
Study: 19586142
Drug: 2‐session, counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐session, counseling and education, HIV/HCV risk reduction intervention (C&E) added to usual treatment
Study: 17542057
Drug: Standard 30-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 30-min infusion of gemcitabine (1200 mg/m(2))
Study: 17542057
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose rate (FDR) infusion of gemcitabine (10 mg/(m(2) x min))
Study: 15482353
Drug: Sumatriptan 100
Normalized name: sumatriptan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 100 mg tablets (early treatment)
Study: 15482353
Drug: Sumatriptan 100
Normalized name: sumatriptan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 100 mg tablets (late treatment)
Study: 9691162
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (n = 12)
Study: 3360972
Drug: Metronidazole (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (250 mg three times daily)
Study: 3360972
Drug: Alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1 mg orally)
Study: 3360972
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg IV)
Study: 28103915
Drug: Community health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community health volunteers (CHVs) providing health education, oral rehydration solutions, and zinc tablets for diarrhea, and diagnosing malaria.
Study: 26581144
Drug: VAC (vincristine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC (vincristine, dactinomycin, cyclophosphamide) or VAC alternating with VTC (topotecan) for 42 weeks, with local therapy of 50.4 Gy radiation therapy with or without delayed primary excision starting at week 12 for group III patients.
Study: 26581144
Drug: Local therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapy with 36-41.4 Gy radiation therapy for group I/II alveolar RMS patients.
Study: 21338720
Drug: Topical phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical phenytoin dressing once daily
Study: 9217619
Drug: 10-minute office-staff
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-minute office-staff administered screen for malnutrition/weight loss, visual impairment, hearing loss, cognitive impairment, urinary incontinence, depression, physical limitations, and reduced leg mobility.
Study: 9217619
Drug: 10-minute office-staff
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-minute office-staff administered screen
Study: 3542916
Drug: Standard schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard schedule (5 fractions per week of 180 to 200 cGy per day, total dose of 6600‐7380 cGy)
Study: 24715213
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) followed by D2 gastrectomy
Study: 23429740
Drug: NUCAI (nurse-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUCAI (nurse-led psychosocial intervention), consisting of six bimonthly 45-minute counseling sessions, aimed at managing physical, psychological, and social consequences of HNC and its treatment.
Study: 1464343
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 1 mg
Study: 1464343
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 2 mg
Study: 1464343
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 3 mg
Study: 378005
Drug: Intravenous cefamandole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefamandole
Study: 28940962
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow therapy at 15 L/min
Study: 28940962
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow therapy at 30 L/min
Study: 28940962
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow therapy at 45 L/min
Study: 27221555
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPI) long-term therapy
Study: 17993008
Drug: Shenwu gelatin
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenwu gelatin capsule (5 capsules, 3 times a day for 3 months)
Study: 17993008
Drug: Aniracetam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aniracetam (2 capsules) with 3 placebo capsules (3 times a day for 3 months)
Study: 10413761
Drug: HCC (heparin-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCC (heparin-coated circuits)
Study: 7675881
Drug: Complete caffeine
Normalized name: ACETAMINOPHEN 500 mg / PAMABROM 25 mg / PYRILAMINE MALEATE 15 mg ORAL TABLET [Midol Complete Caffeine Free]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete caffeine deprivation (100% of daily caffeine intake)
Study: 7675881
Drug: Partial caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Partial caffeine deprivation (50% of daily caffeine intake)
Study: 7675881
Drug: No caffeine
Normalized name: caffeine Oral Tablet [No Doz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No caffeine deprivation (0% of daily caffeine intake)
Study: 6110953
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years of maintenance treatment
Study: 6110953
Drug: 5 years
Normalized name: Dymadon 5 Years Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 years of maintenance treatment
Study: 29872264
Drug: levodropropizine CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodropropizine CR 90 mg two times in the fed state (TF)
Study: 29872264
Drug: levodropropizine CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodropropizine CR 90 mg two times in the fasted state (T)
Study: 29872264
Drug: levodropropizine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodropropizine IR 60 mg three times in the fasted state (R)
Study: 21818642
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g ginger
Study: 21818642
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g ginger
Study: 21818642
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g ginger
Study: 2649632
Drug: Propranolol at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol at 80 mg
Study: 2649632
Drug: Atenolol at
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol at 50 mg
Study: 2649632
Drug: Metoprolol at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol at 100 mg
Study: 2649632
Drug: Renal clearance
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal clearance and urinary excretion
Study: 26200405
Drug: levobupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine + tramadol 50 mg
Study: 26200405
Drug: levobupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine + fentanyl 150 mcg
Study: 26200405
Drug: levobupivacaine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 2.5 mg/ml
Study: 3175579
Drug: Metronidazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1 g suppositories)
Study: 3175579
Drug: Ornidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole (500 mg iv or 500 mg suppositories)
Study: 19422357
Drug: Acid+capsaicin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid+capsaicin (200 ml solution: 180 ml HCL 0.1 M and 2 mg capsaicin in 20 ml solvent)
Study: 17066105
Drug: 25 G
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 G spinal needle
Study: 1836989
Drug: 26 G
Normalized name: Sunmark Lancet Thin 26 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 G spinal needle
Study: 12577392
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection (SMI) plus thrombolytic treatment
Study: 12577392
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment only (Control)
Study: 9435936
Drug: Ciprofloxacin (CF)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CF) 500 mg orally twice daily
Study: 9435936
Drug: Ceftazidime (CT)
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime (CT) 1 g intravenously twice daily
Study: 27012781
Drug: Crushed prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed prasugrel 60-mg loading dose
Study: 22699288
Drug: 0.5 units/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 units/kg/day insulin glargine and glulisine
Study: 22699288
Drug: 0.25 units/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 units/kg/day insulin glargine and glulisine
Study: 22699288
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing groups (0.5 and 0.25 units/kg/day)
Study: 16255837
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (clobetasol propionate 0.05%, betamethasone valerate 0.1%, clobetasone butyrate 0.05%)
Study: 14733854
Drug: Consulting of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consulting of internal medicine (CIM) in primary care
Study: 3168936
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g QID before meals)
Study: 31639790
Drug: Nicorandil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (10 mg, t.i.d., starting 2 days before and continuing for 2 days after the procedure)
Study: 31639790
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard hydration treatment only)
Study: 25111433
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy (behavior activation and problem-solving therapy)
Study: 21654719
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (tri-weekly for 6 weeks)
Study: 15689052
Drug: D‐003 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐003 (20 mg/day)
Study: 8481017
Drug: Ketotifen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (2 to 4 mg per day)
Study: 3115210
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg four times a day)
Study: 3891188
Drug: Sulindac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (200 mg twice a day)
Study: 23784369
Drug: Umeclidinium (10-350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium (10-350 μg)
Study: 23784369
Drug: Umeclidinium (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium (100 μg and above)
Study: 25289942
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide (18 μg)
Study: 21757893
Drug: Marine omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine omega-3 fatty acids (2,080 mg daily for 10 weeks)
Study: 19452380
Drug: Aripiprazole titrated-dose
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole titrated-dose (starting dose 5 mg/day)
Study: 19452380
Drug: Aripiprazole fixed-dose
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole fixed-dose (dose 15 mg/day)
Study: 19452380
Drug: Aripiprazole titrated-dose
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole titrated-dose
Study: 19452380
Drug: Aripiprazole fixed-dose
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole fixed-dose
Study: 16422995
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg i.v.
Study: 8204472
Drug: Cyclosporin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (5 mg/kg daily for 6 weeks)
Study: 3284632
Drug: Marital therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marital therapy designed to enhance intimacy through self-disclosure
Study: 29184167
Drug: Nebivolol (NEB)
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebivolol (NEB) 5/10 mg/day
Study: 29184167
Drug: Atenolol (ATE)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol (ATE) 25/50 mg/day
Study: 25403327
Drug: Rapeseed/canola oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed/canola oil (RA) supplementation (50 g daily for 4 weeks)
Study: 25403327
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (OL) supplementation (50 g daily for 4 weeks)
Study: 22591446
Drug: Motor physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor physical therapy combined with neuromuscular electrical stimulation (NMES) on the tibialis anterior
Study: 22591446
Drug: Motor physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor physical therapy alone
Study: 17559750
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (NIASPAN) 1 g (N1)
Study: 17559750
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (NIASPAN) 2 g (N2)
Study: 15252223
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance therapy at a dosage of 80-100 mg per day
Study: 15252223
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance therapy at a dosage lower than 40 mg per day
Study: 15252223
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance therapy with treatment duration of 90 days or less
Study: 886702
Drug: Preventive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive therapy for the 'intermediate' group (350 persons)
Study: 31451420
Drug: Inactivated varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated varicella zoster virus vaccine
Study: 23547959
Drug: Students unfamiliar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Students unfamiliar with treatment and remedies for WMSD
Study: 21467701
Drug: Efavirenz with
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz with fixed-dose lamivudine and abacavir
Study: 21467701
Drug: Ritonavir-boosted atazanavir
Normalized name: atazanavir and ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted atazanavir with fixed-dose lamivudine and abacavir
Study: 19628136
Drug: Project ALERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Project ALERT (school-based drug prevention program)
Study: 3804564
Drug: Ephedrine/methylxanthine mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine/methylxanthine mixture (22 mg ephedrine, 30 mg caffeine, 50 mg theophylline)
Study: 25072937
Drug: Nω‐hydroxy‐nor‐L‐arginine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nω‐hydroxy‐nor‐L‐arginine (0.1 mg/min)
Study: 22594233
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser irradiation after root canal therapy and conservative periodontal treatment
Study: 22594233
Drug: Root canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal therapy and conservative periodontal treatment (scaling and root planning)
Study: 9856368
Drug: verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil (240 mg once a day)
Study: 9856368
Drug: chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorthalidone (25 mg once a day)
Study: 8873633
Drug: Pentoxifylline therapy
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline therapy